Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 385204, 11 pages
http://dx.doi.org/10.1155/2015/385204
Research Article

The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study

1Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, No. 155, Section 2, Li-Nong Road, Taipei 112, Taiwan
2Department of Chinese Medicine, Taipei City Hospital, Yangming Branch, No. 105 Yusheng Street, Shilin District, Taipei City 111, Taiwan
3Taiwan Association for Traditional Chinese Medicine of Family, 9F., No. 105 Yusheng Street, Shilin District, Taipei City 111, Taiwan

Received 17 June 2014; Revised 19 August 2014; Accepted 15 September 2014

Academic Editor: Pau-Chung Chen

Copyright © 2015 Wei-Lung Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. K. Osborne, “Tamoxifen in the treatment of breast cancer,” The New England Journal of Medicine, vol. 339, no. 22, pp. 1609–1618, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials,” The Lancet, vol. 378, no. 9793, pp. 771–784, 2011. View at Publisher · View at Google Scholar
  3. A. B. Grey, J. P. Stapleton, M. C. Evans, and I. R. Reid, “The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women,” The Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 11, pp. 3191–3195, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Fisher, J. P. Costantino, D. L. Wickerham et al., “Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study,” Journal of the National Cancer Institute, vol. 97, no. 22, pp. 1652–1662, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Fornander and L. E. Rutqvist, “Adjuvant tamoxifen and second cancers,” The Lancet, vol. 1, no. 8638, p. 616, 1989. View at Google Scholar · View at Scopus
  6. B. Haynes and M. Dowsett, “Clinical pharmacology of selective estrogen receptor modulators,” Drugs and Aging, vol. 14, no. 5, pp. 323–336, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. V. C. Jordan, M. M. Gottardis, and P. G. Satyaswaroop, “Tamoxifen-stimulated growth of human endometrial carcinoma,” Annals of the New York Academy of Sciences, vol. 622, pp. 439–446, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Swerdlow and M. E. Jones, “Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study,” Journal of the National Cancer Institute, vol. 97, no. 5, pp. 375–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Fisher, J. P. Costantino, C. K. Redmond, E. R. Fisher, D. L. Wickerham, and W. M. Cronin, “Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14,” Journal of the National Cancer Institute, vol. 86, no. 7, pp. 527–537, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. L. E. Rutqvist, H. Johansson, T. Signomklao, U. Johansson, T. Fornander, and N. Wilking, “Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group,” Journal of the National Cancer Institute, vol. 87, no. 9, pp. 645–651, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. Sasco, “Tamoxifen and menopausal status: risks and benefits,” The Lancet, vol. 347, no. 9003, p. 761, 1996. View at Google Scholar · View at Scopus
  12. J. Bonneterre, B. Thürlimann, J. F. R. Robertson et al., “Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study,” Journal of Clinical Oncology, vol. 18, no. 22, pp. 3748–3757, 2000. View at Google Scholar · View at Scopus
  13. C. C. Reyes-Gibby, X. Wu, M. Spitz et al., “Molecular epidemiology, cancer-related symptoms, and cytokines pathway,” The Lancet Oncology, vol. 9, no. 8, pp. 777–785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Tagliaferri, I. Cohen, and D. Tripathy, “Complementary and alternative medicine in early-stage breast cancer,” Seminars in Oncology, vol. 28, no. 1, pp. 121–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Rakovitch, J. P. Pignol, C. Chartier et al., “Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death,” Breast Cancer Research and Treatment, vol. 90, no. 2, pp. 139–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-N. Lai, C.-T. Wu, and J.-D. Wang, “Prescription pattern of Chinese herbal products for breast cancer in Taiwan: a population-based study,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 891893, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Jia, H. Yan, X. Bu, G. Liu, and Y. Zhao, “Aglycone protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells,” Journal of Clinical Oncology, vol. 22, no. 14, article 9663, 2004, ASCO 2004 Meeting Proceedings (Post-Meeting Edition). View at Google Scholar
  18. Y. Yu, Q. Zhou, Y. Hang, X. Bu, and W. Jia, “Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells,” Cancer, vol. 109, no. 11, pp. 2374–2382, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. H. Lee, Y. T. Tsai, J. N. Lai, and S. K. Lin, “Concurrent use of hypnotic drugs and Chinese herbal medicine therapies among Taiwanese adults with insomnia symptoms: a population-based study,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 987862, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Chen, J. N. Lai, P. C. Chen, and J. D. Wang, “Concurrent use of conventional drugs with Chinese herbal products in Taiwan: a population-based study,” Journal of Traditional and Complementary Medicine, vol. 3, no. 4, pp. 256–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-C. Lee, Y.-T. Huang, Y.-W. Tsai et al., “The impact of universal National Health Insurance on population health: the experience of Taiwan,” BMC Health Services Research, vol. 10, article 225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. Department of Chinese Medicine and Pharmacy MoHaW/Executive Yuan/Taiwan, “List of 100 unified formulae,” http://www.mohw.gov.tw/CHT/DOCMAP/DM1.aspx?f_list_no=758&fod_list_no= 3 918.
  23. Prevention CfDCa, “International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM),” http://www.cdc.gov/nchs/icd/icd9cm.htm.
  24. S. C. Hsieh, J. N. Lai, C. F. Lee, F. C. Hu, W. L. Tseng, and J. D. Wang, “The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 6, pp. 609–619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Friberg, N. Orsini, C. S. Mantzoros, and A. Wolk, “Diabetes mellitus and risk of endometrial cancer: a meta-analysis,” Diabetologia, vol. 50, no. 7, pp. 1365–1374, 2007. View at Google Scholar
  26. L. Bernstein, D. Deapen, S. M. Schwartz et al., “Tamoxifen therapy for breast cancer and endometrial cancer risk,” Journal of the National Cancer Institute, vol. 91, no. 19, pp. 1654–1662, 1999. View at Google Scholar
  27. Department of Chinese Medicine and Pharmacy MoHaW and Executive Yuan Taiwan, “List of 21 most important ancient text in Chinese medicine,” http://www.mohw.gov.tw/cht/DOCMAP/DM1_P.aspx?f_list_no=207&fod_list_no=1196&doc_no=2727.
  28. D. L. Barton, H. Liu, S. R. Dakhil et al., “Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2,” Journal of the National Cancer Institute, vol. 105, no. 16, pp. 1230–1238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Scholey, A. Ossoukhova, L. Owen et al., “Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study,” Psychopharmacology, vol. 212, no. 3, pp. 345–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Luo, S. Hou, G. Dong, T. Chen, L. Liu, and H. Zhou, “Effectiveness of panax ginseng on acute myocardial ischemia reperfusion injury was abolished by flutamide via endogenous testosterone-mediated akt pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 817826, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. S. Kim, I. H. Cho, M. J. Jeong et al., “Therapeutic efect of total ginseng saponin on skin wound healing,” Journal of Ginseng Research, vol. 35, no. 3, pp. 360–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. W. J. Kim, H. Kang, G. J. Choi et al., “Antihyperalgesic effects of ginseng total saponins in a rat model of incisional pain,” The Journal of Surgical Research, vol. 187, no. 1, pp. 169–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Tan, F. Zhou, N. Li et al., “Anti-fatigue effect of ginsenoside Rb1 on postoperative fatigue syndrome induced by major small intestinal resection in rat,” Biological & Pharmaceutical Bulletin, vol. 36, no. 10, pp. 1634–1639, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. C. Sunderland and C. K. Osborne, “Tamoxifen in premenopausal patients with metastatic breast cancer: a review,” Journal of Clinical Oncology, vol. 9, no. 7, pp. 1283–1297, 1991. View at Google Scholar · View at Scopus